QQ客服 官方微博 反馈留言

	Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial
	Xu, Peng-Peng; Fu, Di; Li, Jian-Yong; Hu, Jian-Da; Wang, Xin; Zhou, Jian-Feng; Yu, Hao; Zhao, Xia; Huang, Yao-Hui; Jiang, Lu
刊名	LANCET HAEMATOLOGY
	2019
卷号	6期号:6页码:E328-E337
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4547818
专题	山东大学
作者单位	Shanghai Jiao
推荐引用方式 GB/T 7714	Xu, Peng-Peng,Fu, Di,Li, Jian-Yong,et al. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial[J]. LANCET HAEMATOLOGY,2019,6(6):E328-E337.
APA	Xu, Peng-Peng.,Fu, Di.,Li, Jian-Yong.,Hu, Jian-Da.,Wang, Xin.,...&Liu, 更多.(2019).Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.LANCET HAEMATOLOGY,6(6),E328-E337.
MLA	Xu, Peng-Peng,et al."Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial".LANCET HAEMATOLOGY 6.6(2019):E328-E337.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。